Literature DB >> 12605364

Cell kinetics and genetic instabilities in differentiated type early gastric cancers with different mucin phenotype.

Naomi Shibata1, Jiro Watari, Mikihiro Fujiya, Satoshi Tanno, Yusuke Saitoh, Yutaka Kohgo.   

Abstract

To clarify the biological impact and molecular pathogenesis of cellular phenotype in differentiated-type gastric cancers (DGCs), we investigated cell kinetics and genetic instabilities in early stage of DGCs. A total of 43 early gastric cancers (EGCs) were studied. EGCs were divided into 3 phenotypic categories: gastric (G type, n = 11), ordinary (O type, n = 20), and complete intestinal (CI type, n = 12) based on the combination of HGM, ConA, MUC2, and CD10. Proliferative index (PI), apoptotic index (AI), and p53 overexpression were investigated by immunohistochemical staining with anti-Ki-67, the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling method, and p53 antibody, respectively. Using a high-resolution fluorescent microsatellite analysis system, microsatellite instability (MSI) and loss of heterozygosity (LOH) were examined. Frameshift mutation analysis of transforming growth factor-beta type II receptor (TGF-betaRII) and bcl-2-associated X (BAX) in cancers with MSI was also performed. The mean AI/PI ratio values were 0.04 for G-type, 0.10 for O-type, and 0.13 for CI-type cancers--significantly lower in G type than in O and CI types (P = 0.02 and P = 0.001, respectively). No difference in the incidence of MSI and LOH was seen among the 3 cellular phenotypes. However, the major pattern of MSI, which showed drastic and widely dispersed changes and is related to an increased risk for cancer, was significantly higher in G and O types than in CI type (P <0.005). No frame shift mutations of TGF-betaRII or BAX were found in CI-type cancers. These results indicate that G-type cancers are likely to show more aggressive behaviors than CI-type cancers, and that O-type cancers show the intermediate characteristics of both types. However, the molecular pathogenesis of each phenotypic cancer is not associated with microsatellite alterations. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605364     DOI: 10.1053/hupa.2003.2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma.

Authors:  Fumiaki Toki; Atsushi Takahashi; Ryusuke Aihara; Kyoichi Ogata; Hiroyuki Ando; Tetsuro Ohno; Erito Mochiki; Hiroyuki Kuwano
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Tumor differentiation phenotype in gastric differentiated-type tumors and its relation to tumor invasion and genetic alterations.

Authors:  Kimiyasu Yamazaki; Yusuke Tajima; Reiko Makino; Nobukazu Nishino; Shigeo Aoki; Masanori Kato; Masaaki Sakamoto; Koji Morohara; Tsutomu Kaetsu; Mitsuo Kusano
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers.

Authors:  Masau Sekiguchi; Ryoji Kushima; Ichiro Oda; Haruhisa Suzuki; Hirokazu Taniguchi; Shigeki Sekine; Takeo Fukagawa; Hitoshi Katai
Journal:  J Gastroenterol       Date:  2014-08-21       Impact factor: 7.527

4.  Microsatellite instability is linked to loss of hMLH1 expression in advanced gastric cancers: lack of a relationship with the histological type and phenotype.

Authors:  Tsutomu Mizoshita; Tetsuya Tsukamoto; Xueyuan Cao; Takafumi Otsuka; Seiji Ito; Emiko Takahashi; Shigeo Nakamura; Tsuneya Nakamura; Yoshitaka Yamamura; Masae Tatematsu
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

5.  Predictive factors for lymph node metastasis in early gastric cancer with lymphatic invasion after endoscopic resection.

Authors:  Ji Won Park; Sangjeong Ahn; Hyuk Lee; Byung-Hoon Min; Jun Haeng Lee; Poong-Lyul Rhee; Kyoung-Mee Kim; Jae J Kim
Journal:  Surg Endosc       Date:  2017-04-04       Impact factor: 4.584

6.  Gastric and intestinal phenotypic cell marker expressions in gastric differentiated-type carcinomas: association with E-cadherin expression and chromosomal changes.

Authors:  Koji Morohara; Yusuke Tajima; Kentaro Nakao; Nobukazu Nishino; Shigeo Aoki; Masanori Kato; Masaaki Sakamoto; Kimiyasu Yamazaki; Tsutomu Kaetsu; Satoshi Suzuki; Akira Tsunoda; Tetsuhiko Tachikawa; Mitsuo Kusano
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-31       Impact factor: 4.553

7.  Predictive factors for local recurrence and incomplete resection of early gastric cancer treated by endoscopic resection: a Western experience.

Authors:  Fábio Y Hondo; Fauze Maluf-Filho; Humberto Setsuo Kishi; Ricardo Sato Uemura; Luciano Okawa; Ivan Cecconello; Paulo Sakai
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

8.  Quantitative analysis of the effect of Helicobacter pylori on the expressions of SOX2, CDX2, MUC2, MUC5AC, MUC6, TFF1, TFF2, and TFF3 mRNAs in human gastric carcinoma cells.

Authors:  Kazuyuki Matsuda; Kazuyoshi Yamauchi; Takehisa Matsumoto; Kenji Sano; Yoshio Yamaoka; Hiroyoshi Ota
Journal:  Scand J Gastroenterol       Date:  2008-01       Impact factor: 2.423

9.  Differences in genetic instability and cellular phenotype among Barrett's, cardiac, and gastric intestinal metaplasia in a Japanese population with Helicobacter pylori.

Authors:  Jiro Watari; Kentaro Moriichi; Hiroki Tanabe; Ryu Sato; Mikihiro Fujiya; Hiroto Miwa; Kiron M Das; Yutaka Kohgo
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

10.  Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions.

Authors:  Y Tajima; K Yamazaki; N Nishino; K Morohara; T Yamazaki; T Kaetsu; S Suzuki; M Kawamura; K Kumagai; M Kusano
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.